Cardiovasc Drugs Ther

• 

  Publication Venue For

  • Regional Variations in Alirocumab Dosing Patterns in Patients with Heterozygous Familial Hypercholesterolemia During an Open-Label Extension Study..  34:515-523. 2020
  • Impact of Polypharmacy and P-Glycoprotein- and CYP3A4-Modulating Drugs on Safety and Efficacy of Oral Anticoagulation Therapy in Patients with Atrial Fibrillation..  33:615-623. 2019
  • BSCR Autumn Meeting Abstracts..  261-274. 2019
  • The Use of Oral Beta-Blockers and Clinical Outcomes in Patients with Non-ST-Segment Elevation Acute Coronary Syndromes: a Long-Term Follow-Up Study..  32:435-442. 2018
  • Prevalence of Prediabetes and Undiagnosed Diabetes in Patients with HFpEF and HFrEF and Associated Clinical Outcomes..  31:545-549. 2017
  • Efficacy and Safety of Alternate-Day Versus Daily Dosing of Statins: a Systematic Review and Meta-Analysis..  31:419-431. 2017
  • Navigating the Future of Cardiovascular Drug Development-Leveraging Novel Approaches to Drive Innovation and Drug Discovery: Summary of Findings from the Novel Cardiovascular Therapeutics Conference..  31:445-458. 2017
  • Effect of Apixaban on All-Cause Death in Patients with Atrial Fibrillation: a Meta-Analysis Based on Imputed Placebo Effect..  31:295-301. 2017
  • Efficacy and Safety of Alirocumab in Patients with Heterozygous Familial Hypercholesterolemia and LDL-C of 160 mg/dl or Higher..  30:473-483. 2016
  • Novel oral anticoagulants after acute coronary syndromes..  26:265-271. 2012
  • Stroke prevention in atrial fibrillation..  25:561-570. 2011
  • Differential effects of vitamin d receptor agonists on gene expression in neonatal rat cardiomyocytes..  25:215-222. 2011
  • An introduction to small non-coding RNAs: miRNA and snoRNA..  25:151-159. 2011